Baseline patient characteristics
| Gender, n (%) | |
| Females | 56 (49) |
| Males | 59 (51) |
| Age* (years) | 31 (16–72) |
| Disease features | |
| Area of involvement, n (%) | |
| Left colon | 25 (22) |
| Pancolitis | 90 (78) |
| Duration* (years) | 7 (0.4–24) |
| Acute severe, n (%) | 42 (37) |
| Ulcerative colitis activity score† | |
| Acute severe* | 11 (10–12) |
| Moderately severe* | 8 (6–10) |
| Current smoker, n (%) | 2 (2) |
| Former smoker, n (%) | 12 (10) |
| Medications at initiation | |
| Corticosteroids | |
| Intravenous, n (%) | 58 (50) |
| Prednisone, n (%) | 47 (41) |
| Dose, mg‡ | 40 (20–50) |
| ⩾20 mg/day, n (%) | 89 (77) |
| Dependence ⩾1 year, n (%) | 24 (21) |
| Mesalamine, n (%) | 78 (68) |
| Azathioprine, n (%) | 26 (23) |
| CRP ⩽5 mg/L,§ n (%) | 21 (18) |
| pANCA positive, n (%) | 73 (63) |
*Values are median and range.
†Measured by the Mayo score: range is from 0 to 12, with higher scores indicating more severe disease.
‡Values are in prednisone equivalents at initiation of infliximab and are median and interquartile range.
§A value of CRP ⩽5 mg/L is within the normal range.
CRP, C-reactive protein; pANCA, perinuclear antineutrophil cytoplasmic antibody.